TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines

Hjelm, Brooke E.; Kilbourne, Jacquelyn; Herbst-Kralovetz, Melissa M.

doi:10.4161/hv.27147

Cited by 29 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, virosomes may not require the addition of adjuvants and so may be the more attractive of the two options as oral delivery vehicles [183]. Results in mice following intra-nasal application of Noravirus-based VLPs have been encouraging and will perhaps in time lend themselves to the oral route [184,185] although it may be essential to incorporate these lipid based systems in enteric capsule based formulations to enhance their oral effectiveness and protect them from the lipid digesting gastrointestinal environment.…”

Section: Virus-like Particlesmentioning

confidence: 99%

Delivery strategies to enhance oral vaccination against enteric infections

Davitt

Lavelle

2015

Advanced Drug Delivery Reviews

133

102

View full text Add to dashboard Cite

Section: Virus-like Particlesmentioning

confidence: 99%

Delivery strategies to enhance oral vaccination against enteric infections

Davitt

Lavelle

2015

Advanced Drug Delivery Reviews

133

102

View full text Add to dashboard Cite

“…We speculate this variability due to non-uniform uptake of VLPs from the small intestine once released from the capsules 47 . Future studies should incorporate permeation enhancers such as surfactants or fatty acids, or a mucosal adjuvant, along with enteric protection to the orally delivered VLPs vaccines 48, 49 .…”

Section: Discussionmentioning

confidence: 99%

Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus

Saboo

Tumban

Peabody³

et al. 2016

Mol. Pharmaceutics

View full text Add to dashboard Cite

Existing vaccines against human papillomavirus (HPV) require continuous cold-chain storage. Previously, we developed a bacteriophage virus-like particle (VLP) based vaccine for Human Papillomavirus (HPV) infection, which elicits broadly neutralizing antibodies against diverse HPV types. Here, we formulated these VLPs into a thermostable dry powder using a multi-component excipient system and by optimizing the spray drying parameters using a half-factorial design approach. Dry powder VLPs were stable after spray drying and after long-term storage at elevated temperatures. Immunization of mice with a single dose of reconstituted dry powder VLPs that were stored at 37°C for more than a year elicited high anti-L2 IgG antibody titers. Spray dried thermostable, broadly protective L2 bacteriophage VLPs vaccine could be accessible to remote regions of the world (where ~84% of cervical cancer patients reside) by eliminating the cold-chain requirement during transportation and storage.

show abstract

“…120 Recently, it has been shown that the i.n delivery of virus like particles (VLPs) in combination with TLR7 or TLR9 agonists led to a significantly better dose-sparing effects than TLR3, TLR5 or TLR8 agonists for the induction of specific and functional antibody responses in the respiratory, gastrointestinal, and reproductive tracts. 121 Chitosan microparticles and cationic chitosan derivatives are obtained from natural crab shells, composed of chitin derivatives, and are potent activators of macrophages and NK cells. Their administration by the i.n route combined with antigen induced high levels of IgA in the serum of mice and non-human primates.…”

Section: Mucosal Adjuvantsmentioning

confidence: 99%